



June 28, 2007 General Meeting

Lille (France), Cambridge (Massachusetts, United States), July 4th, 2007 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company involved in drug discovery and development in the field of cardiovascular, inflammatory and metabolic disease, announces the results of its General Meeting held on June 28, 2007 at the headquarter of the company.

There was a quorum for this Annual Ordinary and Extraordinary General Meeting amounting to 90,75%.

During this meeting, the shareholders among others approved the accounts for 2006.

About GENFIT

An emerging biopharmaceutical company, GENFIT studies the deregulation of genes implicated in the most widespread diseases. GENFIT's teams identify new therapeutic targets and develop drug candidates. GENFIT's programs, conducted in partnership with industrial pharmaceutical companies such as SANOFI-AVENTIS, SOLVAY, PIERRE FABRE, MERCK AG, SERVIER deal with the most prevalent metabolic and inflammatory diseases. GENFIT's specific development of drugs focuses on global cardiovascular risks, attacking several pathologies (atherosclerosis, diabetes, obesity, etc.) simultaneously, using a single molecule.

GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development, carried out by GENFIT alone or in partnership. At the end of June 2007, four molecules are in Phase II : 2 proprietary products and 2 molecules in partnership with Sanofi-Aventis (AVE8134 and AVE0847). In addition, another molecule in partnership with Sanofi-Aventis (AVE0897) is completing Phase I.

With facilities in Lille and Cambridge (USA), the Company was founded by Jean-François MOUNEY, Chairman of the Management Board, with the scientific support of Professor Jean-Charles FRUCHART, Chairman of the Supervisory Board. At the end of June 2007, its staff was comprised of 130 employees, including nearly 100 scientists (www.genfit.com).

Contacts:

GENFIT

Jean-François Mouney – Chairman of the Management Board
03 20 16 40 00
Headquarter : 885, Avenue Eugène Avinée – 59120 LOOS - FRANCE

MILESTONES – Press Relations

Bruno Arabian
01 70 08 04 13 / 06 87 88 47 26 - milestones@milestones-fr.com